Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Propofol-Lipuro

Phase 3Small molecule

UUniversity Hospital, Grenoble

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Sedation

NCT04016246

Clinical

Trials by Indication[1]

Sedation2 trials

Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy

Completed·LLena Nilsson·N/A·NCT03357393·150 enrolled

Respiratory Effect of the LISA Method with Sedation by Propofol Versus Absence of Sedation.

Active, not recruiting·UUniversity Hospital, Grenoble·Phase 3·NCT04016246·233 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Propofol-Lipuro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Propofol-Lipuro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Propofol-Lipuro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Grenoble company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Grenoble

Related News